Last updated: September 21, 2026
Triheptanoin is marketed in the United States as Dojolvi by Ultragenyx Pharmaceutical Inc. The product is an orphan therapy for long-chain fatty acid oxidation disorders, or LC-FAODs. Its commercial profile is defined by a small diagnosed population, chronic use, high annual treatment cost, specialist prescribing, and limited direct competition. Revenue has grown since the 2020 U.S. launch, but market expansion depends on diagnosis rates, reimbursement, international access, and clinical adoption outside the most severe pediatric cases.
What is triheptanoin and what is Dojolvi approved to treat?
Dojolvi is a prescription liquid containing triheptanoin, a synthetic triglyceride composed of three seven-carbon fatty acids. The FDA approved it in July 2020 as a source of calories and fatty acids for patients with molecularly confirmed LC-FAODs [1].
LC-FAODs impair the mitochondrial oxidation of long-chain fatty acids. Patients can experience hypoketotic hypoglycemia, rhabdomyolysis, cardiomyopathy, muscle weakness, and recurrent metabolic crises. Triheptanoin provides calories and heptanoate-derived metabolites that can support energy production through anaplerosis, replenishing intermediates in the tricarboxylic acid cycle.
The product is administered orally or enterally. Patients generally take it with meals and divide the daily dose across feedings. Dosing is weight-based and requires dietitian and metabolic-specialist oversight.
FDA regulatory status
| Item |
Status |
| Brand |
Dojolvi |
| Active ingredient |
Triheptanoin |
| Sponsor |
Ultragenyx Pharmaceutical Inc. |
| FDA application |
NDA 213687 |
| U.S. approval |
July 21, 2020 |
| Indication |
Source of calories and fatty acids for patients with LC-FAODs |
| Patient population |
Pediatric and adult patients |
| Regulatory designation |
Orphan drug |
| Dosage form |
Oral and enteral liquid |
| Main prescribers |
Metabolic disease specialists, pediatric neurologists, geneticists, and specialized dietitians |
The product was approved on the basis of clinical and real-world evidence supporting reductions in metabolic decompensation and related hospital utilization. Its label does not position triheptanoin as a cure or as a replacement for all dietary management.
How large is the triheptanoin market?
The addressable market is small in patient count but large in revenue per treated patient. LC-FAODs are rare inherited disorders, with prevalence varying by subtype and geography. Diagnosis is supported by newborn screening in some countries, but screening coverage is uneven.
Commercial market size depends on four factors:
- The number of genetically confirmed patients.
- The proportion of diagnosed patients treated with triheptanoin.
- Persistence with chronic treatment.
- Reimbursement for a high-cost nutritional therapy.
The U.S. is the principal commercial market because of broader newborn screening, specialist infrastructure, and orphan-drug reimbursement mechanisms. Europe and selected Asia-Pacific markets provide additional growth but typically require country-by-country pricing and reimbursement decisions.
Market expansion drivers
The strongest demand drivers are:
- Earlier diagnosis through expanded newborn screening.
- Greater recognition of milder and late-onset LC-FAOD phenotypes.
- Reduction in hospital admissions and metabolic crises.
- Use in adults who were previously managed with emergency dietary protocols.
- Greater physician familiarity with long-term triheptanoin therapy.
- Expanded access through specialty pharmacies and manufacturer support programs.
The main constraints are low disease prevalence, treatment complexity, variable payer policies, gastrointestinal tolerability, and the need for sustained adherence to a high-calorie liquid regimen.
How has Dojolvi revenue developed?
Dojolvi revenue has followed the typical orphan-drug launch pattern: an initial ramp after approval, followed by growth as diagnosis, payer coverage, and specialist adoption expand.
Ultragenyx reports product-level revenue in its annual and quarterly filings. Public company disclosures show Dojolvi sales increasing materially from the first full commercial year through 2023, although the product remains smaller than Crysvita in Ultragenyx’s portfolio [2][3].
| Period |
Commercial development |
Financial interpretation |
| 2020 |
U.S. launch after July FDA approval |
Limited first-year contribution |
| 2021 |
First full commercial year |
Early-center and specialist adoption |
| 2022 |
Broader reimbursement and international expansion |
Continued patient additions |
| 2023 |
More established U.S. base |
Increased recurring revenue and greater contribution to rare-disease portfolio |
| 2024 onward |
Maturation of U.S. business and geographic expansion |
Growth increasingly depends on penetration and persistence rather than launch availability |
Dojolvi’s economic model is attractive because treatment is chronic and generally continues for years. New patient starts create recurring revenue, while discontinuation risk is tied to tolerability, clinical response, disease progression, and access interruptions.
The product’s revenue trajectory is less dependent on blockbuster-scale volume than on maintaining a high net price and adding patients through specialist networks. Ultragenyx’s disclosures indicate that Dojolvi has become a meaningful growth product within the company’s rare-disease portfolio, although it does not carry the same absolute revenue scale as Crysvita.
What is the pricing and reimbursement model for triheptanoin?
Dojolvi is distributed through specialty channels and requires payer authorization in many jurisdictions. The commercial model typically includes:
- Prior authorization based on confirmed LC-FAOD diagnosis.
- Documentation from a metabolic specialist.
- Specialty pharmacy fulfillment.
- Dietitian support and dosing management.
- Manufacturer assistance for eligible patients.
- Reauthorization based on continued clinical need.
The high annual cost reflects orphan-drug economics, manufacturing complexity, chronic dosing, and the small patient population. The payer value proposition is based on avoiding emergency admissions, intensive care, rhabdomyolysis episodes, and long-term complications.
Coverage can be more difficult for adults with milder disease or less frequent crises. Payers may also examine whether patients can maintain adequate nutrition through conventional dietary management. These restrictions can delay treatment initiation and create revenue volatility at the patient level.
What competitive threats affect triheptanoin?
Triheptanoin has limited direct pharmaceutical competition. The main alternatives are disease-management approaches rather than branded drugs.
Direct competitors
No broadly established, FDA-approved competing triheptanoin product has displaced Dojolvi in the U.S. market. A competitor would need to overcome formulation, orphan-drug exclusivity, physician familiarity, and payer contracting barriers.
Indirect competitors
Indirect alternatives include:
- Medium-chain triglyceride supplementation.
- Modified long-chain-fat dietary regimens.
- Frequent carbohydrate intake.
- Emergency intravenous glucose.
- Avoidance of fasting and prolonged exertion.
- Supportive treatment for rhabdomyolysis and cardiomyopathy.
- Clinical-trial therapies directed at metabolic energy production.
These approaches remain part of comprehensive management. They can limit the number of patients who receive triheptanoin, particularly those with milder disease or infrequent symptoms.
Competitive pipeline risk
The most credible long-term threat is not a generic oil product. It is a therapy that improves fatty-acid oxidation, prevents metabolic crises, or reduces the need for dietary intervention. Potential competitors could include gene therapies, enzyme or substrate-modifying treatments, mitochondrial-metabolism therapies, and improved medical foods.
Such products would face substantial development challenges because LC-FAODs are genetically heterogeneous, patient populations are small, and clinical endpoints are difficult to standardize.
What patents and exclusivity protect Dojolvi?
Dojolvi benefits from several layers of protection, although orphan-drug exclusivity is more important commercially than conventional composition-of-matter exclusivity.
Regulatory exclusivity
The FDA granted orphan-drug exclusivity for the approved LC-FAOD indication. The standard U.S. orphan exclusivity period is seven years from approval under the Orphan Drug Act [4]. For a July 21, 2020 approval, the core exclusivity period generally runs to July 21, 2027, subject to statutory exceptions.
Orphan exclusivity prevents FDA approval of the same drug for the same disease or condition during the protected period. It does not prevent all competing products, and it does not block a different drug with a different active ingredient.
Patent protection
Triheptanoin itself is an old chemical class and does not receive the same effective protection as a newly discovered molecular entity. Commercial protection therefore depends more heavily on:
- Formulation claims.
- Pharmaceutical composition claims.
- Dosing regimens.
- Methods of treating LC-FAODs.
- Manufacturing and purification methods.
- Device or packaging claims.
- Regulatory exclusivity.
The Orange Book position should be evaluated against the current FDA listing and applicable patent certifications. Dojolvi’s practical barrier to generic entry is not limited to a single active-ingredient patent. A challenger would need to assess the approved formulation, label, methods of use, orphan exclusivity, and potential infringement exposure.
When does triheptanoin lose exclusivity?
The principal defined U.S. regulatory date is July 2027, when the seven-year orphan-drug exclusivity period associated with the 2020 approval is expected to expire. Patent expiry dates may extend beyond that date if valid, enforceable patents cover the product, formulation, manufacturing process, or approved use.
Generic entry is therefore unlikely to be determined by orphan exclusivity alone. A company seeking approval could pursue:
- A full NDA.
- A 505(b)(2) application.
- A generic pathway if the reference-product requirements are met.
- A product with a different formulation or delivery approach.
The commercial launch date would depend on patent certifications, litigation, settlement terms, regulatory approval, and the challenger’s ability to establish pharmaceutical equivalence and clinical substitutability.
What is the Paragraph IV and litigation risk?
A Paragraph IV challenge would allege that a listed patent is invalid, unenforceable, or not infringed. Publicly visible litigation risk should be monitored through:
- FDA Orange Book patent listings.
- Paragraph IV notice letters.
- ANDA litigation under the Hatch-Waxman Act.
- Federal district court complaints.
- Patent Trial and Appeal Board proceedings.
- Settlement announcements and launch-date provisions.
The risk profile is currently more limited than for a high-volume small-molecule drug because the market is small, the dosage form is specialized, and the reference product is used under close clinical supervision. Those factors reduce the expected return for a generic challenger.
A challenger could still pursue the market if it identifies a scalable oral-liquid formulation, obtains favorable reimbursement, and launches after orphan exclusivity or through a non-infringing pathway. The likely first competitive event would be a specialty alternative rather than rapid multi-generic erosion.
How strong is the triheptanoin commercial and patent estate?
The commercial estate is moderately strong, with the following advantages:
- Orphan-drug status.
- Limited diagnosed population.
- Chronic treatment duration.
- Specialist prescribing.
- Established physician and payer infrastructure.
- Manufacturing and formulation know-how.
- High switching friction for patients receiving stable therapy.
Its weaknesses are equally clear:
- The underlying molecule is not a novel chemical entity.
- Clinical use is concentrated in a small population.
- Dietary and nutritional alternatives remain available.
- Payers can impose authorization requirements.
- The product requires careful dosing and administration.
- Orphan exclusivity has a defined end date.
- A differentiated competitor could avoid direct patent overlap.
The strongest protection is the combined effect of regulatory exclusivity, patient scarcity, specialist distribution, clinical familiarity, and manufacturing execution. Patent protection alone is less decisive than it would be for a conventional new chemical entity.
Which companies are challenging Ultragenyx in triheptanoin?
No major branded pharmaceutical competitor has established a comparable U.S. commercial position in triheptanoin. Competition is more likely to emerge from:
- Specialty generic manufacturers.
- Medical-food companies.
- Rare-disease companies developing metabolic therapies.
- Academic or venture-backed gene-therapy developers.
- Manufacturers of alternative medium-chain triglyceride formulations.
Ultragenyx retains a first-mover advantage through its regulatory approval, physician relationships, patient services, and real-world treatment experience. The primary competitive question is whether a new therapy can reduce metabolic events more effectively or provide a simpler administration profile.
What is the outlook for triheptanoin revenue?
The base-case outlook is continued growth at a slower rate than the initial launch period. Revenue should benefit from diagnosis expansion and recurring treatment, but the product’s absolute ceiling is constrained by disease prevalence.
Bull-case scenario
A stronger outcome would result from:
- Wider newborn screening.
- Greater use in adults.
- Improved payer coverage.
- Reduced treatment discontinuation.
- Additional international approvals.
- Evidence showing fewer hospitalizations and lower total medical costs.
Base-case scenario
The most likely trajectory is steady specialty growth through patient additions, geographic expansion, and improved persistence. Annual growth would gradually moderate as the highest-propensity patients are treated.
Downside scenario
Revenue could weaken if:
- Payers impose stricter utilization controls.
- Patients discontinue because of gastrointestinal intolerance or administration burden.
- New metabolic therapies reduce demand.
- Generic or specialty competition launches after exclusivity expiry.
- International reimbursement fails to support premium pricing.
Key Takeaways
- Triheptanoin is marketed as Dojolvi by Ultragenyx for LC-FAODs.
- The FDA approved Dojolvi on July 21, 2020.
- The product has a small patient population but high recurring revenue potential.
- Commercial growth depends on diagnosis, specialist adoption, reimbursement, and long-term persistence.
- U.S. orphan-drug exclusivity generally runs through July 21, 2027.
- Direct competition remains limited, but dietary alternatives and future metabolic therapies create indirect pressure.
- Formulation, dosing, manufacturing, and method-of-use protection are commercially relevant because triheptanoin is not a newly discovered chemical class.
- The most probable revenue path is continued growth with gradual moderation as the diagnosed and treated population matures.
FAQs
Is triheptanoin the same as a medium-chain triglyceride oil?
No. Triheptanoin is a synthetic triglyceride containing three seven-carbon fatty acids. Conventional medium-chain triglyceride products generally contain six- to 12-carbon fatty acids and do not have the same formulation or regulatory status.
Is Dojolvi a biologic or a small-molecule drug?
Dojolvi is a nonbiologic pharmaceutical product. It is an orally administered triglyceride formulation rather than a monoclonal antibody, cell therapy, or gene therapy.
Can a generic company launch triheptanoin immediately after July 2027?
Not necessarily. A post-exclusivity launch would still depend on FDA approval, patent certifications, litigation, formulation requirements, manufacturing capability, and payer access.
Does triheptanoin treat all fatty acid oxidation disorders?
No. Dojolvi is approved specifically for LC-FAODs. Its regulatory indication does not automatically extend to medium-chain or short-chain fatty acid oxidation disorders.
What is the biggest long-term risk to Dojolvi revenue?
The largest strategic risk is a therapy that provides comparable or superior prevention of metabolic crises with simpler administration or broader disease coverage. Generic or specialty competition is a later risk tied to orphan-exclusivity expiry and the enforceability of applicable patents.
References
- U.S. Food and Drug Administration. (2020). Dojolvi prescribing information. https://www.accessdata.fda.gov
- Ultragenyx Pharmaceutical Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov
- Ultragenyx Pharmaceutical Inc. (2024). Quarterly and annual financial results. https://ir.ultragenyx.com
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
